Wells Fargo & Company Immatics N.V. Transaction History

Wells Fargo & Company

$407 Billion
Q2 2024

A detailed history of Wells Fargo & Company transactions in Immatics N.V. stock. As of the latest transaction made, Wells Fargo & Company holds 14 shares of IMTX stock, worth $129. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Holding current value

$129

% of portfolio

0.0%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2024 Aug 13, 2024	BUY	$9.78 - $13.49 $136 - $188	14 New	14 $0
Q4 2022 Feb 13, 2023	BUY	$8.05 - $11.58 $6,021 - $8,661	748 New	748 $6,000

Others Institutions Holding IMTX

# of Institutions

101

Shares Held

76.8M

Call Options Held

571K

Put Options Held

210K

Rtw Investments, LP New York, NY

10M
Shares

$92.5 Million
1.94% of portfolio
Wellington Management Group LLP Boston, MA

9.54M
Shares

$88.2 Million
0.02% of portfolio
Perceptive Advisors LLC New York, NY

8.09M
Shares

$74.8 Million
2.72% of portfolio
T. Rowe Price Investment Management, Inc. Baltimore, MD

7.43M
Shares

$68.8 Million
0.05% of portfolio
Baker Bros. Advisors LP New York, NY

6.44M
Shares

$59.6 Million
1.0% of portfolio

View Full List

About Immatics N.V.

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $705M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

More about IMTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account